Abbas Nazir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Abbas Nazir has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Jacob L. Glass
Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY
33 shared publications - Ross L. Levine
Memorial Sloan Kettering Cancer Center, New York, USA
33 shared publications - Aaron D. Viny
Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY
27 shared publications - Abdul Karzai
Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
27 shared publications - Amritha Varshini Hanasoge Somasundara
Human Oncology and Pathogenesis Program
27 shared publications - Andrew Jun Dunbar
Human Oncology and Pathogenesis Program and Leukemia service Memorial Sloan Kettering Cancer Center New York NY USA
27 shared publications
Latest Publications
- Open Access
Spatiotemporal profiling reveals the role of inflammatory niche in driving prostate cancer
Prostate cancer (PCa) is a lethal malignancy that displays profound resistance to immune checkpoint blockade (ICB), via mechanisms that are poorly understood. Here, we investigate the causes of CD8 T cell exhaustion and mechanisms of tumor progression in a PCa animal model, by single cell and spatial profiling, along a time course, following orthotopic transplantation of RB1/TP53/PTEN-deficient mouse organoids, competent to express neoantigens. The resulting tumors were castration resistant, consisting of largely basal and L2 malignant cells with upregulated inflammatory gene programs, and a specific spatial distribution of macrophages, cancer associated fibroblast (CAF) subtypes, and CD8 T-cells that was not previously reported. Using Zman-seq, we demonstrate that the effector function of tumor-infiltrating CD8 T cells was rapidly impaired as early as 24hrs after their infiltration, likely driven by signals from proinflammatory macrophages, Ccl2 - Jak2 + inflammatory CAFs, and malignant basal cells, thus driving resistance to ICB. Interestingly, dual blockade of JAK1/2 and PD1 induced potent anti-tumor effects in tumor epithelial cells, decreased malignant epithelial cells and pro-inflammatory macrophages, and increased the proportion of normal ( Pi16 + ) fibroblasts in the TME. Our results underscore the therapeutic potential of targeting JAK1/2 to enhance the efficacy of ICB, providing a rationale for clinical investigation of this combination in PCa.
Open AccessSpatiotemporal profiling reveals the role of inflammatory niche in driving prostate cancer
Prostate cancer (PCa) is a lethal malignancy that displays profound resistance to immune checkpoint blockade (ICB), via mechanisms that are poorly understood. Here, we investigate the causes of CD8 T cell exhaustion and mechanisms of tumor progression in a PCa animal model, by single cell and spatial profiling, along a time course, following orthotopic transplantation of RB1/TP53/PTEN-deficient mouse organoids, competent to express neoantigens. The resulting tumors were castration resistant, consisting of largely basal and L2 malignant cells with upregulated inflammatory gene programs, and a specific spatial distribution of macrophages, cancer associated fibroblast (CAF) subtypes, and CD8 T-cells that was not previously reported. Using Zman-seq, we demonstrate that the effector function of tumor-infiltrating CD8 T cells was rapidly impaired as early as 24hrs after their infiltration, likely driven by signals from proinflammatory macrophages, Ccl2 - Jak2 + inflammatory CAFs, and malignant basal cells, thus driving resistance to ICB. Interestingly, dual blockade of JAK1/2 and PD1 induced potent anti-tumor effects in tumor epithelial cells, decreased malignant epithelial cells and pro-inflammatory macrophages, and increased the proportion of normal ( Pi16 + ) fibroblasts in the TME. Our results underscore the therapeutic potential of targeting JAK1/2 to enhance the efficacy of ICB, providing a rationale for clinical investigation of this combination in PCa.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Patient characteristics for scATAC-Seq
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Patient characteristics for scATAC-Seq
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
ATAC-Seq analysis - MPN vs. TAM
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
ATAC-Seq analysis - MPN vs. TAM
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Patient characteristics for scATAC-Seq
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Patient characteristics for scATAC-Seq
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Phenotypic characterization and Jak2V617F oncogenic dependency in the setting of concomitant Tet2 loss
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Phenotypic characterization and Jak2V617F oncogenic dependency in the setting of concomitant Tet2 loss
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Functional characterization of Jak2RL knock-in/knock-out in vivo
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Functional characterization of Jak2RL knock-in/knock-out in vivo
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Assessment of tamoxifen toxicity on Jak2RL knock-in cells
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Assessment of tamoxifen toxicity on Jak2RL knock-in cells
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Differential responses of Jak2V617F deletion compared to JAK inhibitor therapy in vivo
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Differential responses of Jak2V617F deletion compared to JAK inhibitor therapy in vivo
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Effects of Jak2V617F deletion on MPN stem cell fitness and disease transplantability
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Effects of Jak2V617F deletion on MPN stem cell fitness and disease transplantability
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
RNA-Seq analysis - MPN vs. TAM
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
RNA-Seq analysis - MPN vs. TAM